Halozyme Therapeutics, Inc. (NASDAQ:HALO)
CAPS Rating:
A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.
RSS Headlines
Fool UK
Recs
The potential from a $600 Million deal with Roche sounds good to me.